First Trust Advisors LP Sells 11,897 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

First Trust Advisors LP cut its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 252,420 shares of the company's stock after selling 11,897 shares during the quarter. First Trust Advisors LP owned about 0.20% of Henry Schein worth $17,467,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Versant Capital Management Inc increased its holdings in Henry Schein by 274.6% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $32,000 after acquiring an additional 335 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company's stock worth $41,000 after buying an additional 569 shares during the last quarter. Quent Capital LLC increased its holdings in Henry Schein by 91.2% in the 4th quarter. Quent Capital LLC now owns 677 shares of the company's stock valued at $47,000 after purchasing an additional 323 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after purchasing an additional 143 shares during the last quarter. Finally, City State Bank acquired a new stake in Henry Schein in the 4th quarter valued at approximately $55,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

Shares of NASDAQ HSIC traded down $1.19 during midday trading on Wednesday, reaching $64.97. 1,059,826 shares of the company traded hands, compared to its average volume of 1,619,316. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The stock has a 50-day moving average price of $68.73 and a 200 day moving average price of $71.72. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The company has a market cap of $7.96 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion during the quarter, compared to analysts' expectations of $3.25 billion. During the same period in the prior year, the business posted $0.66 EPS. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. Sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares of the company's stock, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the transaction, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several recent analyst reports. Barrington Research reaffirmed an "outperform" rating and set a $90.00 price objective on shares of Henry Schein in a research report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and increased their target price for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. StockNews.com cut Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Jefferies Financial Group raised their price target on Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Finally, Piper Sandler reduced their price objective on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a report on Wednesday. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $80.20.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.